Table 8.
Results of cost-effectiveness analysis: base-case
| Brolucizumab (A) | Aflibercept (B) | Difference (A-B) | |
|---|---|---|---|
| Outcomes | |||
| Life years (LYs) | 9.00 | 9.00 | 0.00 |
| Quality adjusted life years (QALYs) | 6.43 | 6.32 | 0.11 |
| Direct costs (€) | |||
| Treatment acquisition costs (€) | 46,821 | 58,265 | - 11,444 |
| Treatment administration costs (€) | 15,130 | 17,277 | - 2147 |
| Disease monitoring costs (€) | 1663 | 1895 | - 232 |
| TREA management costs (€) | 115 | 47 | 68 |
| Direct costs of blindness (€) | 7632 | 8157 | - 525 |
| Direct costs of low vision (€) | 4626 | 6025 | - 1399 |
| Total direct costs (€) | 75,988 | 91,666 | −15,679 |
| Incremental cost-effectiveness ratio (ICER) | |||
| ICER (brolucizumab vs aflibercept) (€/QALY) | Brolucizumab dominant | ||
ICER Incremental cost-effectiveness ratio, LYs life years, QALYs Quality adjusted life years, TRAE Treatment-related adverse event